by Legal Desire

8 November 2025

Latham & Watkins Advises 4D Molecular Therapeutics on US$100 Million Offering of Common Stock and Pre-Funded Warrants

Capital Markets & IPO Healthcare & Life Sciences Expected to close

Advising firms

Latham & Watkins LLP

Issuer acting for 4D Molecular Therapeutics

Deal team

17 lawyers named

Lawyer	Firm	Seniority	Practice	Office
Mark Roeder Lead	Latham & Watkins LLP	Partner	corporate	Bay Area
John Williams Lead	Latham & Watkins LLP	Partner	corporate	Bay Area
Raul Gonzalez-Casarrubias	Latham & Watkins LLP	Associate	corporate	Not stated
Lexi Zintel	Latham & Watkins LLP	Associate	corporate	Not stated
Keran Huang	Latham & Watkins LLP	Associate	corporate	Not stated
Elizabeth Richards	Latham & Watkins LLP	Partner	regulatory	Washington, D.C.
Betty Pang	Latham & Watkins LLP	Partner	regulatory	Bay Area
Chad Jennings	Latham & Watkins LLP	Counsel	regulatory	Washington, D.C.
Evan Miller	Latham & Watkins LLP	Associate	regulatory	Not stated
Heather Deixler	Latham & Watkins LLP	Partner	data privacy and cybersecurity	Bay Area
Sarah Zahedi	Latham & Watkins LLP	Associate	data privacy and cybersecurity	Not stated
Grace Lee	Latham & Watkins LLP	Partner	tax	Bay Area
Dennis Poehland	Latham & Watkins LLP	Associate	tax	Not stated
Maj Vaseghi	Latham & Watkins LLP	Partner	benefits and compensation	Bay Area
Christopher Hazuka	Latham & Watkins LLP	Partner	intellectual property	San Diego/Bay Area
Robert Yeh	Latham & Watkins LLP	Counsel	intellectual property	San Diego
Kristina Funahashi	Latham & Watkins LLP	Associate	intellectual property	Not stated

14 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value: USD 100m (US$100 million)
What the figure measures: Issue size
Client: 4D Molecular TherapeuticsIssuer
Counterparties: Not stated